Masimo Co. (NASDAQ:MASI) Shares Sold by Amalgamated Bank

Amalgamated Bank trimmed its holdings in shares of Masimo Co. (NASDAQ:MASI) by 4.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 30,390 shares of the medical equipment provider’s stock after selling 1,535 shares during the period. Amalgamated Bank’s holdings in Masimo were worth $3,562,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Mission Wealth Management LP acquired a new stake in Masimo during the fourth quarter worth about $267,000. Harvest Fund Management Co. Ltd raised its position in shares of Masimo by 2,888.9% during the 4th quarter. Harvest Fund Management Co. Ltd now owns 538 shares of the medical equipment provider’s stock worth $62,000 after purchasing an additional 520 shares during the period. Linden Thomas Advisory Services LLC lifted its holdings in shares of Masimo by 2.2% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 8,539 shares of the medical equipment provider’s stock worth $1,001,000 after purchasing an additional 183 shares during the last quarter. Handelsbanken Fonder AB boosted its position in Masimo by 6.8% during the 4th quarter. Handelsbanken Fonder AB now owns 9,430 shares of the medical equipment provider’s stock valued at $1,105,000 after purchasing an additional 600 shares during the period. Finally, CWM LLC grew its stake in Masimo by 13.5% during the 4th quarter. CWM LLC now owns 1,318 shares of the medical equipment provider’s stock worth $154,000 after buying an additional 157 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on MASI shares. Wells Fargo & Company raised shares of Masimo from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $117.00 to $160.00 in a report on Monday, March 25th. Piper Sandler boosted their target price on shares of Masimo from $117.00 to $126.00 and gave the company a “neutral” rating in a research note on Wednesday. Jefferies Financial Group restated a “hold” rating and issued a $121.00 price target (up previously from $107.00) on shares of Masimo in a research note on Tuesday, January 30th. BTIG Research boosted their price objective on Masimo from $145.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, March 25th. Finally, StockNews.com upgraded Masimo from a “sell” rating to a “hold” rating in a research report on Friday, March 29th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $138.71.

Masimo Price Performance

Shares of NASDAQ:MASI opened at $124.16 on Friday. The stock’s 50 day moving average price is $136.10 and its 200 day moving average price is $119.62. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.18 and a quick ratio of 1.22. The stock has a market cap of $6.57 billion, a price-to-earnings ratio of 82.23 and a beta of 0.99. Masimo Co. has a 12 month low of $75.22 and a 12 month high of $176.29.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, May 7th. The medical equipment provider reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.06. The company had revenue of $492.80 million for the quarter, compared to the consensus estimate of $487.70 million. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The company’s quarterly revenue was down 12.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.87 EPS. Equities research analysts anticipate that Masimo Co. will post 3.51 earnings per share for the current fiscal year.

Insider Transactions at Masimo

In related news, Director Craig B. Reynolds sold 40,000 shares of the stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $136.17, for a total transaction of $5,446,800.00. Following the completion of the sale, the director now directly owns 7,406 shares of the company’s stock, valued at $1,008,475.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 9.70% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.